Nymox Pharmaceutical plans $12 million at-the-market sales agreement

Financing arranged with Chardan to finance general corporate purposes

By Devika Patel

Knoxville, Tenn., Feb. 9 – Nymox Pharmaceutical Corp. negotiated a $12 million at-the-market agreement with Chardan Capital Markets, LLC, according to a prospectus supplement filed Tuesday with the Securities and Exchange Commission.

Chardan will be paid a 3% commission.

Proceeds will be used for general corporate purposes and working capital.

The biotechnology company is based in Silver Spring, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.